Literature DB >> 21115908

Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.

Sisi Wang1, Hongyong Zhang, Liang Cheng, Christopher Evans, Chong-Xian Pan.   

Abstract

AIM: To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects.
MATERIALS AND METHODS: The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry.
RESULTS: Synergism was observed when the bladder cancer cell line 5637 cells were treated with gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine. In contrast, moderate antagonism was observed when cells were treated with carboplatin followed by gemcitabine. Cell cycle analysis showed that the combined effect of these two drugs was cell cycle disturbance.
CONCLUSION: Different doses and administration schedules affect the antitumor effect of carboplatin/gemcitabine combination that may have clinical significance in the treatment for bladder cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21115908      PMCID： PMC4562399     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  23 in total

Review 1.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.

Authors:  Melanie B McMahon; Misty D Bear; Samuel K Kulp; Michael L Pennell; Cheryl A London
Journal:  Am J Vet Res       Date:  2010-07       Impact factor: 1.156

3.  Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.

Authors:  M J Edelman; H Quam; B Mullins
Journal:  Cancer Chemother Pharmacol       Date:  2001-08       Impact factor: 3.333

Review 4.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

5.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

Authors:  P Huang; S Chubb; L W Hertel; G B Grindey; W Plunkett
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

6.  Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.

Authors:  Helena Linardou; Gerassimos Aravantinos; Eleni Efstathiou; Charalambos Kalofonos; Athanasios Anagnostopoulos; Charalambos Deliveliotis; Dimitrios Bafaloukos; Meletios Athanasios Dimopoulos; Aristotelis Bamias
Journal:  Urology       Date:  2004-09       Impact factor: 2.649

7.  An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.

Authors:  Judith A Smith; Jubilee Brown; Miranda C Martin; Lois M Ramondetta; Judith K Wolf
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

8.  Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.

Authors:  E Bajetta; S C Stani; D De Candis; N Zaffaroni; N Zilembo; D Cortinovis; S Aglione; L Mariani; B Formisano; P Bidoli
Journal:  Ann Oncol       Date:  2003-02       Impact factor: 32.976

9.  Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.

Authors:  D D Ross; D P Cuddy
Journal:  Biochem Pharmacol       Date:  1994-10-18       Impact factor: 5.858

10.  Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.

Authors:  C J van Moorsel; H M Pinedo; G Veerman; A M Bergman; C M Kuiper; J B Vermorken; W J van der Vijgh; G J Peters
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640
View more
  6 in total

1.  The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

Authors:  Shu-Xiong Zeng; Yanjun Zhu; Ai-Hong Ma; Weimin Yu; Hongyong Zhang; Tzu-Yin Lin; Wei Shi; Clifford G Tepper; Paul T Henderson; Susan Airhart; Jian-Ming Guo; Chuan-Liang Xu; Ralph W deVere White; Chong-Xian Pan
Journal:  Clin Cancer Res       Date:  2017-08-14       Impact factor: 12.531

2.  Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells.

Authors:  Acharaporn Duangjai; Kui Luo; Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2013-12-04       Impact factor: 5.571

3.  A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.

Authors:  Kruti S Soni; Divya Thomas; Thomas Caffrey; Kamiya Mehla; Fan Lei; Kelly A O'Connell; Satish Sagar; Subodh M Lele; Michael A Hollingsworth; Prakash Radhakrishnan; Tatiana K Bronich
Journal:  J Pharmacol Exp Ther       Date:  2019-01-25       Impact factor: 4.030

4.  Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.

Authors:  Chong-Xian Pan; Hongyong Zhang; Clifford G Tepper; Tzu-yin Lin; Ryan R Davis; James Keck; Paramita M Ghosh; Parkash Gill; Susan Airhart; Carol Bult; David R Gandara; Edison Liu; Ralph W de Vere White
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

Review 5.  The Central Role of Amino Acids in Cancer Redox Homeostasis: Vulnerability Points of the Cancer Redox Code.

Authors:  Milica Vučetić; Yann Cormerais; Scott K Parks; Jacques Pouysségur
Journal:  Front Oncol       Date:  2017-12-21       Impact factor: 6.244

6.  Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.

Authors:  Anne Steins; Eva A Ebbing; Aafke Creemers; Amber P van der Zalm; Rajni A Jibodh; Cynthia Waasdorp; Sybren L Meijer; Otto M van Delden; Kausilia K Krishnadath; Maarten C C M Hulshof; Roelof J Bennink; Cornelis J A Punt; Jan Paul Medema; Maarten F Bijlsma; Hanneke W M van Laarhoven
Journal:  Int J Cancer       Date:  2019-05-07       Impact factor: 7.396
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.